Literature DB >> 6721988

Pharmacokinetics of prednisone and its metabolite prednisolone in children with nephrotic syndrome during the active phase and in remission.

G Gatti, E Perucca, G M Frigo, L D Notarangelo, L Barberis, A Martini.   

Abstract

The kinetics at steady state of prednisone and its metabolite prednisolone were determined in nine nephrotic children during the active phase of the disease and in remission. There were no differences in serum prednisone levels between the two occasions. Prednisone levels were lower than prednisolone levels. Total serum prednisolone levels were significantly lower during the active phase than in remission (AUC: 2452 +/- 207 vs 3392 +/- 293 ng ml-1 h respectively). Half-life values were similar on both occasions. The binding of prednisolone to serum proteins was markedly impaired during the active phase as compared to the remission. Free fraction values correlated positively with total drug concentration. A negative correlation between free fraction and serum albumin level was found during the active phase. Free prednisolone levels during the active phase did not differ significantly from those observed during remission (AUC: 937 +/- 128 vs 847 +/- 81 ng ml-1 h respectively). These data indicate that pharmacokinetic changes are unlikely to be responsible for alterations in steroid responsiveness in nephrotic patients with hypoalbuminaemia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6721988      PMCID: PMC1463411          DOI: 10.1111/j.1365-2125.1984.tb02367.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  11 in total

Review 1.  THE EFFECTS OF STRUCTURAL ALTERATION ON THE ANTI-INFLAMMATORY PROPERTIES OF HYDROCORTISONE.

Authors:  L H SARETT; A A PATCHETT; S L STEELMAN
Journal:  Fortschr Arzneimittelforsch       Date:  1963

Review 2.  Clinical pharmacokinetics of prednisone and prednisolone.

Authors:  M E Pickup
Journal:  Clin Pharmacokinet       Date:  1979 Mar-Apr       Impact factor: 6.447

3.  Prednisone side-effects and serum-protein levels. A collaborative study.

Authors:  G P Lewis; W J Jusko; L Graves; C W Burke
Journal:  Lancet       Date:  1971-10-09       Impact factor: 79.321

4.  Corticosteroid analysis in biological fluids by high-performance liquid chromatography.

Authors:  J Q Rose; W J Jusko
Journal:  J Chromatogr       Date:  1979-03-01

5.  Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion.

Authors:  B M Frey; F J Frey
Journal:  Br J Clin Pharmacol       Date:  1982-02       Impact factor: 4.335

Review 6.  Monitoring prednisone and prednisolone.

Authors:  W J Jusko; J Q Rose
Journal:  Ther Drug Monit       Date:  1980       Impact factor: 3.681

7.  Altered prednisolone kinetics in patients with the nephrotic syndrome.

Authors:  F J Frey; B M Frey
Journal:  Nephron       Date:  1982       Impact factor: 2.847

8.  Effect on nephrotic syndrome on absorption and disposition of prednisolone in children.

Authors:  M L Rocci; B M Assael; A C Appiani; A Edefonti; W J Jusko
Journal:  Int J Pediatr Nephrol       Date:  1982-09

9.  Determination of unbound valproic acid concentration in plasma by equilibrium dialysis and gas--liquid chromatography: methodological aspects and observations in epileptic patients.

Authors:  R Riva; F Albani; A Baruzzi; I Galvani; E Perucca
Journal:  Ther Drug Monit       Date:  1982       Impact factor: 3.681

10.  Plasma protein-binding parameters of prednisolone in immune disease patients receiving long-term prednisone therapy.

Authors:  J G Wagner; D Wexler; I T Ağabeyoğlu; R F Bergstrom; E Sakmar; D R Kay
Journal:  J Lab Clin Med       Date:  1981-04
View more
  11 in total

1.  Pharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study.

Authors:  Anna Carmela P Sagcal-Gironella; Catherine M T Sherwin; Rommel G Tirona; Michael J Rieder; Hermine I Brunner; Alexander A Vinks
Journal:  Clin Ther       Date:  2011-10-07       Impact factor: 3.393

2.  Pharmacokinetics of prednisolone in children with nephrosis.

Authors:  P F Miller; C J Bowmer; J Wheeldon; J T Brocklebank
Journal:  Arch Dis Child       Date:  1990-02       Impact factor: 3.791

3.  MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children.

Authors:  Anna Wasilewska; Grzegorz Zalewski; Lech Chyczewski; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2006-10-17       Impact factor: 3.714

4.  Pharmacokinetics of prednisolone in children with acute lymphoblastic leukaemia.

Authors:  I Choonara; J Wheeldon; P Rayner; M Blackburn; I Lewis
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Should we stop dosing steroids per body surface area for nephrotics?

Authors:  Guido Filler; Lisa A Robinson
Journal:  Pediatr Nephrol       Date:  2015-12-28       Impact factor: 3.714

Review 6.  Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation.

Authors:  Troels K Bergmann; Katherine A Barraclough; Katie J Lee; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2012-11       Impact factor: 6.447

Review 7.  IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome.

Authors:  Agnes Trautmann; Olivia Boyer; Elisabeth Hodson; Arvind Bagga; Debbie S Gipson; Susan Samuel; Jack Wetzels; Khalid Alhasan; Sushmita Banerjee; Rajendra Bhimma; Melvin Bonilla-Felix; Francisco Cano; Martin Christian; Deirdre Hahn; Hee Gyung Kang; Koichi Nakanishi; Hesham Safouh; Howard Trachtman; Hong Xu; Wendy Cook; Marina Vivarelli; Dieter Haffner
Journal:  Pediatr Nephrol       Date:  2022-10-21       Impact factor: 3.651

8.  Effect of obesity on response to cardiovascular drugs in pediatric patients with renal disease.

Authors:  Sherif Hanafy; Maury Pinsk; Fakhreddin Jamali
Journal:  Pediatr Nephrol       Date:  2008-12-13       Impact factor: 3.714

9.  Evaluation of in vivo efficacy and toxicity of prednisolone-loaded hydrogel-based drug delivery device.

Authors:  Amit Kumar De; Plaban Bhattacharya; Sriparna Datta; Arup Mukherjee
Journal:  Int J Pharm Investig       Date:  2013-10

Review 10.  Pharmacology and pharmacogenetics of prednisone and prednisolone in patients with nephrotic syndrome.

Authors:  Anne M Schijvens; Rob Ter Heine; Saskia N de Wildt; Michiel F Schreuder
Journal:  Pediatr Nephrol       Date:  2018-03-16       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.